Physician profile
Robin Fernandes
NPI 1255747713
$8,219.00
in general payments reported to CMS, 2019-2025
25 companies · $857 in 2025
The $857 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $413 · 2021: $1,357 · 2022: $1,739 · 2023: $3,307 · 2024: $546 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,449 · Travel and Lodging: $1,135 · Grant: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.35 |
| Travel and Lodging | $1,134.61 |
| Grant | $1,126.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,844.63 | 2021-2025 | Avvigo Guidance System, Watchman Flx |
| Abbott Laboratories | $1,704.50 | 2021-2025 | Mitraclip, Aveir, Amplatzer Talisman |
| Abiomed | $717.59 | 2020-2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $575.49 | 2020-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $442.47 | 2021-2023 | |
| Medtronic, INC. | $416.53 | 2021-2024 | Corevalve Evolut R, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Janssen Pharmaceuticals, INC | $381.91 | 2021-2023 | Xarelto |
| Biotronik INC. | $336.82 | 2022 | |
| Amgen INC. | $214.77 | 2022 | |
| Heartflow, INC. | $211.02 | 2025 | |
| Novo Nordisk INC | $193.88 | 2023-2025 | Wegovy |
| Kestra Medical Technology Services, INC. | $185.19 | 2025 | Assure Wcd |
| Irhythm Technologies, INC. | $180.19 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $168.38 | 2023-2025 | Camzyos |
| Cook Incorporated | $140.85 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $94.98 | 2022-2023 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.82 | 2022-2024 | Jardiance |
| Zoll Circulation INC | $70.29 | 2021 | |
| Alnylam Pharmaceuticals INC. | $56.47 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $52.84 | 2023 | Optimizer |
| Terumo Medical Corporation | $43.00 | 2023 | Optitorque, Angio-Seal, Glidewire |
| Inari Medical, INC. | $39.32 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Chiesi USA, INC. | $23.97 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $18.45 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.64 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Fernandes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.